Science · Wednesday, September 2, 2026
NIH/NIAID: rare antibodies that blocked alpha-gal (red-meat) allergy in lab tests
The File desk · Sep 2, 2026, 2:00 PM UTC
Status
Confirmed as an NIH news release of preclinical laboratory findings. No human trial is claimed.
National Institutes of Health researchers reported Sept. 1, 2026, that they identified rare antibodies that could inform an intervention for alpha-gal syndrome (AGS), a tick-bite-associated condition that can cause allergic reactions to a molecule in red meat and other animal products. In laboratory tests, the antibodies blocked human allergic antibodies from binding to red-meat allergens. NIH said about 110,000 suspected U.S. cases have been identified since 2010. No clinical trial is claimed.
NIH wrote: “National Institutes of Health (NIH) researchers have discovered rare antibodies that could inform the development of an intervention for alpha-gal syndrome (AGS), an emerging tick-bite-associated condition that can lead to allergic reactions to a molecule in red meat and other animal products.”
The Sept. 1, 2026, release said that in laboratory tests the antibodies acted as a biological shield, blocking human allergic antibodies from binding to red meat allergens. The paper is Cho et al., Journal of Clinical Investigation, DOI 10.1172/JCI192370. NIAID’s John Powers said there is currently no specific treatment or prevention other than avoiding red meat. NIH said approximately 110,000 suspected cases have been identified in the U.S. since 2010.
This is preclinical laboratory work. No human trial is claimed in the NIH release or in the JCI paper as retrieved.
What is still unknown or disputed
- No clinical trial is claimed.
- The 110,000 suspected U.S. cases since 2010 is NIH’s figure; NIH said the true number is likely higher because cases are often not identified.
Primary sources
Every claim in this story is drawn from the documents below. If a fetch failed, that is recorded on the card.
Source 1
NIH researchers identify rare antibodies with potential to combat alpha-gal syndrome
National Institutes of Health · September 1, 2026
National Institutes of Health (NIH) researchers have discovered rare antibodies that could inform the development of an intervention for alpha-gal syndrome (AGS), an emerging tick-bite-associated condition that can lead to allergic reactions to a molecule in red meat and other animal products. Approximately 110,000 suspected cases of the syndrome have been identified in the U.S. since 2010.
https://www.nih.gov/news-events/news-releases/nih-researchers-identify-rare-antibodies-potential-combat-alpha-gal-syndrome
Source 2
Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens
Journal of Clinical Investigation · September 1, 2026
Cho H, et al. Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. Journal of Clinical Investigation. 2026. DOI: https://doi.org/10.1172/JCI192370
https://doi.org/10.1172/JCI192370